Germany· DE-A57-96558b8596991c41
Lamina / Retina Comp.
A medicinal product containing fasciculus opticus bovis dil. d10, lamina quadrigemina bovis dil. d10, retina et chorioidea bovis dil. d10, registered in Germany by Weleda Ag.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Fasciculus Opticus Bovis Dil. D10, Lamina Quadrigemina Bovis Dil. D10, Retina Et Chorioidea Bovis Dil. D10
- Manufacturer
- Weleda Ag
- Country
- Germany (DE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d25794a3-d0aa-481a-80d7-474c90d8310b GET /v1/drugs/d25794a3-d0aa-481a-80d7-474c90d8310b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Subcutaneous Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Fasciculus Opticus Bovis Dil. D10, Lamina Quadrigemina Bovis Dil. D10, Retina Et Chorioidea Bovis Dil. D10",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about fasciculus opticus bovis dil. d10, lamina quadrigemina bovis dil. d10, retina et chorioidea bovis dil. d10.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.